Myriad Genetics (MYGN) Gains from Investment Securities (2016 - 2025)
Historic Gains from Investment Securities for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $300000.0.
- Myriad Genetics' Gains from Investment Securities fell 9000.0% to $300000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 4671.53%. This contributed to the annual value of $13.4 million for FY2024, which is 5227.27% up from last year.
- Latest data reveals that Myriad Genetics reported Gains from Investment Securities of $300000.0 as of Q3 2025, which was down 9000.0% from $5.8 million recorded in Q1 2025.
- Over the past 5 years, Myriad Genetics' Gains from Investment Securities peaked at $8.7 million during Q1 2024, and registered a low of $200000.0 during Q2 2022.
- Moreover, its 5-year median value for Gains from Investment Securities was $1.8 million (2021), whereas its average is $2.8 million.
- In the last 5 years, Myriad Genetics' Gains from Investment Securities surged by 32500.0% in 2022 and then tumbled by 9000.0% in 2025.
- Quarter analysis of 5 years shows Myriad Genetics' Gains from Investment Securities stood at $2.9 million in 2021, then crashed by 48.28% to $1.5 million in 2022, then changed by 0.0% to $1.5 million in 2023, then decreased by 20.0% to $1.2 million in 2024, then plummeted by 75.0% to $300000.0 in 2025.
- Its Gains from Investment Securities stands at $300000.0 for Q3 2025, versus $5.8 million for Q1 2025 and $1.2 million for Q4 2024.